prescribed with caution in In clinical trials with pregnant women, the systemic
Candidal infection (including vaginal and nonvaginal candidiasis; either symptomatic or confirmed by culture) and vaginitis (including vulvovaginitis, vulvovaginal disorder, vaginal discharge, and trichomonal vaginitis) have been reported in about 13.3 and 7.2% of pregnant patients receiving clindamycin phosphate vaginal cream for 7 days. So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to). Adverse effects have been reported in about 23% of pregnant patients receiving intravaginal clindamycin and have required discontinuance of the drug in about 2% of such patients. The systemic bioavailability of intravaginally administered clindamycin 2% vaginal cream (Cleocin) is about 5% and that of the suppositories after three 100 mg daily doses is almost 30%. milk. Click Continue to return to page.This online session has expired due to inactivity. 2. alcohol base which will cause burning and irritation of the eye. EVOCLIN (clindamycin phosphate) Foam, 1% contains 10 mg of clindamycin as clindamycin phosphate, USP per gram. Results of other studies indicate that cure rates obtained with a single 5-g dose of clindamycin phosphate vaginal cream (Clindesse) are superior to placebo and comparable to those obtained with a 7-day regimen of clindamycin vaginal cream (Cleocin). Other adverse effects reported in pregnant patients receiving intravaginal clindamycin include fungal infections and pruritus (in areas other than at the application site) in 1.7 and 1.1%, respectively; these effects were not reported in pregnant women receiving placebo.
In clinical studies evaluating the gel containing clindamycin phosphate 1% in combination with benzoyl peroxide 5% that is prepared at the time of dispensing (BenzaClin), dry skin was reported during treatment in 12% and erythema, peeling, pruritus, or sunburn were reported in 1-2% of patients. been associated with an increased frequency of It is not known whether clindamycin is excreted in human
In one survey, diarrhea reportedly occurred in less than 0.1% of 73,000 patients using extemporaneous preparations of clindamycin hydrochloride or clindamycin phosphate.Heartburn, nausea, vomiting, diarrhea, constipation, and abdominal pain reportedly have occurred in patients receiving intravaginal clindamycin. CDC states that clindamycin vaginal preparations should only be used during the first half of pregnancy.Reproduction studies in rats and mice using subcutaneous or oral clindamycin in dosages of 100-600 mg/kg daily have not revealed evidence of impaired fertility or harm to the fetus. Clindamycin phosphate is used topically alone or in conjunction with benzoyl peroxide in the treatment of inflammatory acne vulgaris. Patients should be warned to discontinue use of clindamycin and to notify their clinician if GI symptoms such as diarrhea occur during topical or intravaginal therapy. can be absorbed in sufficient amounts to produce systemic effects (see Clindamycin Phosphate Topical Solution is contraindicated
clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin
administration of clindamycin during the second and third trimesters has not
Reproduction studies in rats receiving oral clindamycin dosages up to 300 mg/kg daily (31 times the usual human dosage) have not revealed evidence of impaired fertility or mating ability.Although it is not known whether clindamycin is distributed into milk following topical or intravaginal application, the drug is distributed into milk following systemic administration. Access Coupon. The US Centers for Disease Control and Prevention (CDC) states that treatment of bacterial vaginosis is indicated in Intravaginal metronidazole therapy results in clinical cure rates comparable to those reported with a 7-day oral metronidazole regimen; intravaginal clindamycin cream appears to be less effective than the metronidazole regimens. Do Not Store at Temperatures Above 120 degrees F (49 degrees C) Store at controlled room temperature (between 68 and 77 degrees F) EVOCLIN Foam contains clindamycin (1%) as clindamycin phosphate, at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic foam vehicle consisting of cetyl alcohol, ethanol (58%), polysorbate 60, potassiumhydroxide, propylene Peak serum clindamycin concentrations approximately 14 hours (range: 4-24 hours) after administration averaged 13 ng/mL (range: 6-34 ng/mL) and 16 ng/mL (range: 7-26 ng/mL) on days 1 and 7 of therapy, respectively.
Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan. clindamycin phosphate topical gel 1%: rated 4 out of 5 on MakeupAlley. Follow your doctor's orders or the directions on the label.